556 related articles for article (PubMed ID: 24898083)
1. Histone deacetylase inhibitors and cell death.
Zhang J; Zhong Q
Cell Mol Life Sci; 2014 Oct; 71(20):3885-901. PubMed ID: 24898083
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
3. [Structure-activity relationships of histone deacetylase inhibitors].
Tan YM; Huang WY; Yu NF
Yao Xue Xue Bao; 2009 Oct; 44(10):1072-83. PubMed ID: 20055127
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Drug Discov Today; 2019 Mar; 24(3):685-702. PubMed ID: 30776482
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.
Marks PA
Biochim Biophys Acta; 2010; 1799(10-12):717-25. PubMed ID: 20594930
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors: from target to clinical trials.
Kelly WK; O'Connor OA; Marks PA
Expert Opin Investig Drugs; 2002 Dec; 11(12):1695-713. PubMed ID: 12457432
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone deacetylases for heart diseases.
Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
[TBL] [Abstract][Full Text] [Related]
10. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update.
Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A
Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860
[TBL] [Abstract][Full Text] [Related]
11. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
12. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
14. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G
Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335
[TBL] [Abstract][Full Text] [Related]
15. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
17. HDAC Inhibitors.
Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
[TBL] [Abstract][Full Text] [Related]
18. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.
Marks PA
Expert Opin Investig Drugs; 2010 Sep; 19(9):1049-66. PubMed ID: 20687783
[TBL] [Abstract][Full Text] [Related]
19. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
